Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adverum Biotechnologies (GB:0HA3)
LSE:0HA3
RESEARCH TOOLSreports
Holding GB:0HA3?
Track your performance easily
0HA3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.43 - $29.50
Previous Close$6.71
Volume155.00
Average Volume (3M)2.23K
Market Cap
$140.61M
Enterprise Value$40.68M
Total Cash (Recent Filing)$173.83M
Total Debt (Recent Filing)$73.89M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 07, 2024EPS Estimate
-$1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding20,800,903
10 Day Avg. Volume646
30 Day Avg. Volume2,234
Standard Deviation0.25
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)39.06
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.30
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$30.00Price Target Upside347.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Adverum Biotechnologies News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing Phase 2 LUNA study demonstrated a 90-94% reduction in annualized anti-VEGF injections and 68%-85% injection-free rates.
Patient PreferenceResults of the patient preference study were highly positive, with most or all patients preferring ixo-vec vs. their prior treatment regimen.
ValuationADVM shares are now trading 73% below its year-to-date high, presenting an attractive valuation opportunity.
Bears Say
Inflammation And Eye HealthSafety concerns around increased intraocular inflammation/IOI and potential retinal vasculitis appear to be a major gating factor.
Inflammation And VasculitisSafety concerns around increased intraocular inflammation and potential retinal vasculitis appear to be a major gating factor for key opinion leaders.
Safety ConcernsSafety concerns around intraocular inflammation (IOI) appear to be a major gating factor for whether KOLs feel comfortable offering gene therapies to their patients.
---
0HA3 FAQ
What was Adverum Biotechnologies’s price range in the past 12 months?
Adverum Biotechnologies lowest share price was $6.43 and its highest was $29.50 in the past 12 months.
What is Adverum Biotechnologies’s market cap?
Currently, no data Available
When is Adverum Biotechnologies’s upcoming earnings report date?
Adverum Biotechnologies’s upcoming earnings report date is Nov 07, 2024 which is in 60 days.
How were Adverum Biotechnologies’s earnings last quarter?
Adverum Biotechnologies released its earnings results on Aug 12, 2024. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$1.468 by $0.578.
Is Adverum Biotechnologies overvalued?
According to Wall Street analysts Adverum Biotechnologies’s price is currently Undervalued.
Does Adverum Biotechnologies pay dividends?
Adverum Biotechnologies does not currently pay dividends.
What is Adverum Biotechnologies’s EPS estimate?
Adverum Biotechnologies’s EPS estimate is -$1.36.
How many shares outstanding does Adverum Biotechnologies have?
Adverum Biotechnologies has 20,800,903 shares outstanding.
What happened to Adverum Biotechnologies’s price movement after its last earnings report?
Adverum Biotechnologies reported an EPS of -$0.89 in its last earnings report, beating expectations of -$1.468. Following the earnings report the stock price went up 3.108%.
Which hedge fund is a major shareholder of Adverum Biotechnologies?
Among the largest hedge funds holding Adverum Biotechnologies’s share is Versant Venture Management, LLC. It holds Adverum Biotechnologies’s shares valued at 3M.
---
Adverum Biotechnologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (347.09% Upside)
$30.00 (347.09% Upside)
Insider Transactions
Bought Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.59%
12-Months-Change
Fundamentals
Return on Equity
-66.76%
Trailing 12-Months
Asset Growth
5.13%
Trailing 12-Months
Company Description
Adverum Biotechnologies
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
---
0HA3 Stock 12 Month Forecast
Average Price Target
$30.00
▲(347.09% Upside)
Technical Analysis
Adverum Biotechnologies
―
Editas Medicine
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Meiragtx Holdings
―
Best Analysts Covering 0HA3
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-33.30%
reiterated a buy rating 25 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -33.30% per trade.
---